Lupin to co-market Novartis’ asthma drug in India – Business Standard

Lupin to co-market Novartis' asthma drug in India
Business Standard
Lupin Limited and Novartis Healthcare Private Limited (NHPL) yesterday entered into a co-marketing agreement to promote Novartis's indacaterol/glycopyrronium (110 mcg/50 mcg) inhaler, a treatment for chronic obstructive pulmonary disease (COPD), …

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *